Pluristem - A Phase 2, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects with Intermitte

Detalles del proyecto

EstadoFinalizado
Fecha de inicio/Fecha fin11/1/123/31/15

Financiación

  • Pluristem Therapeutics Incorporated: 8.969,00 US$